Dr Vaz Batista on Treating Patients With HER2+ Breast Cancer and Leptomeningeal Carcinomatosis

Dr Drilon on the Potential Benefit of Taletrectinib in ROS1+ NSCLC

Dr Marquina

Dr Hong RMC 6291

Dr Brahmer on the Investigation of FLX475 in NSCLC

Dr Harding on the Rationale for Targeting FGFR2 in Cholangiocarcinoma and Biliary Tract Cancer

Dr Reuss on the Investigation of LP-300 in Lung Adenocarcinoma

Dr. Gadgeel on Unmet Needs in Patients with CNS Metastases in NSCLC

Dr. Porter on the 3-Year Follow-Up Data From the CheckMate-9LA Trial in NSCLC

Dr. Wenham on Rationale for Novel Immunotherapy Combos in Ovarian Cancer

Oncology Nurses Are a 'Lifeline' in Clinical Trial Guidance

Metastatic CRC Nursing Webinar

New Nurses, Don't Give Up

Webinar: Advanced Bladder Cancer

Providers Want Better Training on LGBTQ Populations

Management of Adverse Effects in R/R HER2+ mBC

FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

Bright Future in Advanced Urothelial Cancer

Metastatic Bladder Cancer: Progression After Maintenance

Educating Patients on Maintenance Therapy in mUC

Changing the Standard of Care in Metastatic Bladder Cancer

Practical Management of AEs in Metastatic Bladder Cancer

Precision Medicine in Metastatic Triple Negative Breast Cancer

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

Dr. Lonial Discusses Ongoing Research With BiTEs and CAR T-Cell Therapy in Myeloma

Dr. Azad on the Benefit of Adding Enzalutamide to ADT in mHSPC

Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL

Dr. Masarova on the Safety of JAK Inhibitor/Targeted Therapy Combos in Myelofibrosis

Dr. Gainor on the Evolving Lung Cancer Armamentarium

Dr. Tseng on the Rationale for the TARPSWG Analysis in Retroperitoneal Sarcoma